Revisiting Childhood-Onset Systemic Lupus Erythematosus. Turkish Archives of Pediatrics. 2024; 59:336-344.
.Imaging in Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America. 2024; 50:623-640.
.Assessing disparities through missing race and ethnicity data: results from a juvenile arthritis registry. Frontiers in Pediatrics. 2024; 12:1430981.
.Anti-NMDAR Encephalitis Clinical Practice Guideline: Improving Time to Diagnosis, Treatment, and Hospital Length of Stay. Neurology: Clinical Practice. 2024; 14:e200218.
.Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83:1561-1571.
.Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. The Journal of rheumatology. 2024; 51:1125-1134.
.Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology. 2024; 63:2535-2546.
.S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.
.Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology Online Journal. 2024; 22:88.
.Renal disease in pediatric rheumatology. Current Opinion in Rheumatology. 2024; 36:322-327.
.New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology. 2024; 20:1053-1064.
.Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2024; 76:1566-1572.
.Child Health Needs and the Pediatric Rheumatology Workforce: 2020-2040. Pediatrics. 2024; 153:e2023063678R.
.The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.
.Ultrawidefield Fluorescein Angiography and OCT Findings in Children and Young Adults with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. Ophthalmology Retina. 2024; 8:1107-1112.
.Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.
.Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.
.National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Annals of Internal Medicine. 2024; 177:1547-1557.
.Using a collaborative learning health system approach to improve disease activity outcomes in children with juvenile idiopathic arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network. Frontiers in Pediatrics. 2024; 12:1434074.
.Digital health technology to support patient-centered shared decision making at point of care for juvenile idiopathic arthritis. Frontiers in Pediatrics. 2024; 12:1457538.
.Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.
.Recent Diagnosis of Lupus and Severe Hypertriglyceridemia in a 12-year-old Girl. Pediatrics in review / American Academy of Pediatrics. 2024; 45:601-605.
.Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus. Lupus. 2024; 33:1116-1129.
.2024; 102.
. Blood-based Biomarkers of Neuronal and Glial Damage in Active Major Neuropsychiatric Systemic Lupus Erythematosus (P8-14.012). Neurology.[Formula: see text] Cognitive dysfunction in pediatric systemic lupus erythematosus: current knowledge and future directions. Child Neuropsychology. 2024; 30:818-846.
.Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis. Metabolites. 2024; 14:499.
.Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.
.Clinical outcomes in paediatric tubulointerstitial nephritis and uveitis syndrome (TINU). Eye. 2024; 38:3318-3324.
.Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1090-1098.
.The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease. Pediatric Rheumatology Online Journal. 2024; 21:114.
.Biomarker Changes in Response to Tofacitinib Treatment in Patients with Polyarticular Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1723-1732.
.Deleterious variants in TNFAIP3 are associated with type II and seronegative pediatric autoimmune hepatitis. Journal of Hepatology. 2024; 80:e26-e28.
.Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.
.Needs Assessment of Musculoskeletal Ultrasound Training in North American Pediatric Rheumatology Fellowship Programs. Arthritis Care and Research. 2024; 76:1116-1120.
.Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Journal of Clinical Trials. 2024; 14:563.
.Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2996-3013.e7.
.The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.
.Genetics of Acquired Cytokine Storm Syndromes : Secondary HLH Genetics. Advances in Experimental Medicine and Biology. 2024; 1448:103-119.
.Evaluation of health literacy and its association with medication adherence and quality of life in childhood-onset systemic lupus erythematosus. Lupus. 2024; 33:1004-1011.
.Validation of the ankle-specific pediatric arthritis ultrasound scoring system in children with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2024; 69:152545.
.Diagnostic Accuracy Study of the Pediatric-Specific Ultrasound Scoring System for the Knee Joint in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:251-258.
.Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis. Arthritis and Rheumatology. 2024; 76:1797-1808.
.